Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

Study Overview
=================
Brief Summary
-----------------
Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease. The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections. The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.

Official Title
-----------------
Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

Conditions
-----------------
Shock, Cardiovascular Diseases, Infection

Intervention / Treatment
-----------------
* Biological: Biological samples will be done to evaluate the endothelial and leukocyte senescence.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Circulatory shock patient with health care insurance Exclusion criteria: Patients' refusal to participate in clinical research Pregnant woman Breastfeeding woman A patient with a protective order

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with circulatory shock<br>500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype | Biological: Biological samples will be done to evaluate the endothelial and leukocyte senescence.<br>* Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.<br>|
| Healthy volunteers<br>20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype. | Biological: Biological samples will be done to evaluate the endothelial and leukocyte senescence.<br>* Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells. | Biological samples will be done to evaluate the endothelial and leukocyte senescence. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shock, Cardiovascular Diseases, Infection